EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG: Places Maximum Number of New Shares in Capital Incre...

=------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. =-------------------------------------------------------------------------------

Restructuring & Recapitalisations/Company Information/molecular diagnostic 25.01.2013

Not for distribution in the United States

Berlin, Germany, January 25, 2013 - Today the Executive Board of Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with the approval of the Supervisory Board, has taken the decision to implement the capital increase from authorized capital, the details of which were announced on January 7, 2013, for the maximum number of 3,149,430 new ordinary bearer shares, generating gross proceeds of EUR 4,976,099.

2,811,707 new ordinary bearer shares were taken up by the shareholders at a subscription price of EUR 1.58 per new share during the subscription period which started on January 11, 2013 and ended on January 24, 2013. The remaining 337,723 unsubscribed new shares were sold at the subscription price of EUR 1.58 per new share in a private placement to institutional investors. The private placement was significantly oversubscribed, enabling Epigenomics AG to place the maximum number of new shares. The capital increase was conducted by Kempen & Co.

The registration of the implementation of the capital increase with the commercial register ("Handelsregister") and the admission of the new shares to the regulated market ("regulierter Markt"), Prime Standard, of the Frankfurt Stock Exchange are expected on or around January 29, 2013. Trading in the new shares is expected to begin on January 30, 2013, and delivery of the new shares to the investors is expected on January 31, 2013. With the registration of the implementation of the capital increase the total issued share capital of Epigenomics increases from EUR 8,818,417.00 to EUR 11,967,847.00.

Epigenomics AG intends to use the net proceeds from the share capital increase to finance its current operations.

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities. This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the "Shares") have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.

Contact:

Epigenomics AG Antje Zeise CIRO Manager IR | PR Epigenomics AG Phone: +49 (0) 30 24345 386 ir@epigenomics.com www.epigenomics.com

end of announcement euro adhoc =-------------------------------------------------------------------------------

(END) Dow Jones Newswires

   January 25, 2013 11:00 ET (16:00 GMT)- - 11 00 AM EST 01-25-13